Literature DB >> 2260855

Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis.

K Adachi1, T Kumamoto, S Araki.   

Abstract

The level of soluble interleukin-2 receptor (sIL-2R) was quantitated with enzyme-linked immunosorbent assay in serum and cerebrospinal fluid obtained from 24 patients with multiple sclerosis and 10 patients with other neurological disorders in whom immunological mechanisms are unlikely to participate. The sIL-2R level in the serum and cerebrospinal fluid of patients with multiple sclerosis in relapse was significantly higher compared with patients with multiple sclerosis in remission and with controls. The sIL-2R level, especially in the cerebrospinal fluid, showed higher sensitivity and specificity than other clinical parameters including the cerebrospinal fluid IgG ratio, peripheral lymphocyte CD4/CD8 ratio, cerebrospinal fluid myelin basic protein and oligoclonal bands. Our data suggest that measurement of the sIL-2R level may be useful in evaluating disease activity in patients with multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260855     DOI: 10.1002/ana.410280514

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

2.  Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

Authors:  A Salmaggi; A Dufour; M Eoli; E Corsini; L La Mantia; G Massa; A Nespolo; C Milanese
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

3.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

4.  An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.

Authors:  P Ferrero; P Rocca; P Benna; C De Leo; E Montalenti; L Ravizza; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1992-11

5.  Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.

Authors:  M K Sharief; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

6.  In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

Authors:  M K Sharief; R Hentges; M Ciardi; E J Thompson
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

7.  Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.

Authors:  M Ott; L Demisch; W Engelhardt; P A Fischer
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

8.  Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.

Authors:  Y Zhang; M McClellan; L Efros; D Shi; B Bielekova; M T Tang; V Vexler; J P Sheridan
Journal:  Mult Scler       Date:  2013-07-11       Impact factor: 6.312

Review 9.  The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.

Authors:  Daphne Peerlings; Max Mimpen; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2021-09-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.